Joint Formulary & PAD

Tamsulosin hydrochloride - Benign prostatic hyperplasia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Modified release capsules
Associated Icons :
SPC
Restrictions / Comments :
Preferred
 

Status 2

Non Formulary
Formulations :
  • Modified release tablets
Associated Icons :
NFD1
SPC
Restrictions / Comments :
Important
Use modified release capsules

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tamsulosin hydrochloride
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Flomax, Diffundox, Tabphyn, Flomaxtra
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2

Committee Recommendations (1)

Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option:

  • Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
  • Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)

Alfuzosin is more costly and is therefore not recommended as a 1st-line option.

Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups.

Other Indications

Below are listed other indications that Tamsulosin hydrochloride is used to treat.

  • No records returned.